Berning, B.

tibolone women study postmenopausal women postmenopausal effect group density estrogen treatment trabecular placebo change therapy bone density bone loss month 2.5 menopause hormone replacement therapy trabecular bone density fracture spine osteoporosis bone mass placebo group postmenopausal bone loss replacement increase hormone breast table trial cancer breast cancer raloxifene phalangeal bone density level period 1.25 incidence bone mineral density endometrial treatment groups calcium baseline endometrium medication factor bone metabolism symptom mineral berning metabolism subject phalangeal tissue prevention measurement comparison result gynecol regimen obstet fracture risk bone turnover postmenopausal bone mass marker randomized number serum decrease lactation vasomotor symptoms risk factors placebo-controlled trabecular bone postmenopausal osteoporosis reduction patient